Ratings by Leerink (Daniel Clark)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/9/2026 | ANI Pharmaceuticals | ANIP | New Coverage | Outperform (N/A) |
70.23 (70.70) |
0.67% | Details | |
| 9/9/2026 | Teva Pharma | TEVA | New Coverage | Outperform (N/A) |
36.76 (36.85) |
0.24% | Details | |
| 9/9/2026 | Collegium Pharmaceutical | COLL | New Coverage | Outperform (N/A) |
23.37 (23.36) |
-0.04% | Details | |
| 9/9/2026 | Bausch & Lomb Corp. | BLCO | New Coverage | Outperform (N/A) |
17.73 (17.79) |
0.34% | Details | |
| 9/9/2026 | Amneal Pharmaceuticals | AMRX | New Coverage | Outperform (N/A) |
17.05 (17.25) |
1.17% | Details | |
| 9/9/2026 | Phathom Pharmaceuticals | PHAT | New Coverage | Market Perform (N/A) |
9.43 (8.67) |
-8.06% | Details | |
| 9/9/2026 | Nautilus Biotechnology | NAUT | New Coverage | Outperform (N/A) |
0.93 (1.12) |
20.43% | Details | |
| 9/9/2026 | Pacira Pharmaceuticals | PCRX | New Coverage | Market Perform (N/A) |
25.87 (25.88) |
0.04% | Details | |
| 9/9/2026 | Viatris | VTRS | New Coverage | Outperform (N/A) |
16.61 (16.50) |
-0.66% | Details | |
| 9/9/2026 | Harrow Health | HROW | New Coverage | Outperform (N/A) |
37.85 (37.55) |
-0.79% | Details | |
| 3/10/2026 | Zoetis Inc. | ZTS | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/24/2026 | Elanco Animal Health | ELAN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2026 | IDEXX Laboratories | IDXX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2025 | Elanco Animal Health | ELAN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | Elanco Animal Health | ELAN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | Zoetis Inc. | ZTS | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/3/2025 | IDEXX Laboratories | IDXX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/17/2025 | Zoetis Inc. | ZTS | Downgrade | Market Perform (Outperform) |
151.54 (73.31) |
-51.62% | Details | |
| 7/17/2025 | Elanco Animal Health | ELAN | Upgrade | Outperform (Market Perform) |
14.51 (23.55) |
62.3% | Details | |
| 6/26/2025 | IDEXX Laboratories | IDXX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2025 | IDEXX Laboratories | IDXX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2025 | Elanco Animal Health | ELAN | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/7/2025 | Elanco Animal Health | ELAN | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/6/2025 | Zoetis Inc. | ZTS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2024 | IDEXX Laboratories | IDXX | New Coverage | Outperform (N/A) |
421.75 (515.15) |
22.15% | Details | |
| 12/2/2024 | Elanco Animal Health | ELAN | New Coverage | Market Perform (N/A) |
13.21 (23.55) |
78.27% | Details | |
| 12/2/2024 | Zoetis Inc. | ZTS | New Coverage | Outperform (N/A) |
175.25 (73.31) |
-58.17% | Details |
